• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

National Cancer Survivorship candidate joins Provectus corporate advisory board

Author(s):

Doug Ulman, president and CEO of LIVESTRONG, has been appointed to Provectus Pharmaceuticals’ Corporate Advisory Board.

Knoxville, Tenn. - Doug Ulman, president and CEO of LIVESTRONG, has been appointed to Provectus Pharmaceuticals’ Corporate Advisory Board.

Before his involvement with and leadership of LIVESTRONG, Mr. Ulman founded the Ulman Cancer Fund for Young Adults, a nonprofit organization that provides support, education, and resources for young adults battling cancer.

Mr. Ulman joined LIVESTRONG in 2001 as its director of survivorship and was appointed president and CEO in 2007. A cancer survivor and survivorship advocate, Mr. Ulman reportedly has received several awards for his leadership in the fight against cancer, as well as his contributions to community service.

In 2005, Mr. Ulman was honored by the American Psychosocial Oncology Society and the Association of Oncology Social Workers, and in 2009 and 2010, he was named to the Non-Profit Times Power and Influence Top 50, a tribute given to the top 50 nonprofit executives. He holds various civic and charitable board positions and recently completed serving a four-year term as the chairman of the National Cancer Institute Director’s Consumer Liaison Group.

“I am honored to join Provectus’s Corporate Advisory Board, and I look forward to using my personal cancer and cancer advocacy experiences to help Provectus continue to push patient centered care forward,” Mr. Ulman said in a Provectus news release. “My personal experience with melanoma gives me a unique perspective on the needs of individuals and families who are facing this disease. By providing awareness and guidance to Provectus as it develops its therapies and ongoing corporate strategies, I also expect to further the fight to help those who are, unfortunately, still fighting.”

Related Videos
1 KOL is featured in this series.
2 KOLs are featured in this series.
E. James Song is featured in this video series.
E. James Song is featured in this video series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.